Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.57 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.47 |
| ▸ | CHRNA10 | Q9GZZ6 | 2/20 | 0.47 |
| ▸ | CHRNA9 | Q9UGM1 | 2/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | AHR | P35869 | 3/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30704387 | 0.95 | HDAC1 (0.59) | LTA4HHDAC1PPARDCHRNB4CHRNA3 | |
| SCHEMBL29133439 | 0.95 | HDAC1 (0.59) | LTA4HHDAC1PPARDCHRNB4CHRNA3 | |
| SCHEMBL14481578 | 0.92 | LTA4H (0.60) | LTA4HHDAC1PPARDCHRNB4CHRNA3 | |
| SCHEMBL22149854 | 0.88 | MEN1 (0.56) | LTA4HHDAC1PPARDCHRNB4CHRNA3 | |
| SCHEMBL3793622 | 0.85 | LTA4H (0.60) | LTA4HHDAC1PPARDCHRNB4CHRNA3 | |
| SCHEMBL1544837 | 0.85 | LTA4H (0.60) | LTA4HHDAC1PPARDCHRNB4CHRNA3 | |
| SCHEMBL3794813 | 0.81 | LTA4H (0.60) | LTA4HHDAC1PPARDCHRNB4CHRNA3 | |
| SCHEMBL11788344 | 0.81 | HDAC1 (0.61) | LTA4HHDAC1CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL11505407 | 0.81 | HDAC1 (0.61) | LTA4HHDAC1CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL17402429 | 0.81 | HDAC1 (0.61) | LTA4HHDAC1CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8999994-B2 | Derivatives of propargylamine having neuroprotective capacity for the treatment of Alzheimer's and Parkinson's diseases | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2015-04-07 | — | — | US | disclosed |
| US-20130012522-A1 | NEW DERIVATIVES OF PROPARGYLAMINE HAVING NEUROPROTECTIVE CAPACITY FOR THE TREATMENT OF ALZHEIMER'S AND PARKINSON'S DISEASES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2013-01-10 | — | — | US | disclosed |
| WO-2011113988-A1 | NEW DERIVATIVES OF PROPARGYLAMINE HAVING NEUROPROTECTIVE CAPACITY FOR THE TREATMENT OF ALZHEIMER'S AND PARKINSON'S DISEASES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012522-A1 | NEW DERIVATIVES OF PROPARGYLAMINE HAVING NEUROPROTECTIVE CAPACITY FOR THE TREATMENT OF ALZHEIMER'S AND PARKINSON'S DISEASES | CHRNA4, CHRNB4, CHRNA5 | LTA4H 736/4885HDAC1 1086/4885PPARD 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.